Clinical trials: 18 Years and Over
Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL)
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
This is a hybrid type two study, with two simultaneous development phases. Phase A involves developing a public-private partnership to create the conditions for implementing CAR-T cell therapies in Colombia.
- Conditions
- Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
- Trial name
- ACITAC-001 (NCT07412405)
- Testing
- ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T)
- Volunteers
- 12 people
- Sponsor
- GUSTAVO SALGUERO
Contraception
FC Patch Low: Metabolism Study
The aim of the present study is to investigate the effects of the transdermal patch on the parameters of hemostasis (blood clotting), lipid (fat), and carbohydrate (sugars) metabolism in healthy women who require contraception.
- Trial name
- NCT00933179
- Testing
- Gestodene/EE Patch (BAY86-5016), EE/Levonorgestrel (Microgynon, BAY86-4977)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Influenza
Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03
This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18…
- Trial name
- NCT00731029
- Testing
- Thiomersal free trivalent influenza split vaccine 2002/2003, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
- Where
- Germany
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00505453
- Testing
- Fluviral®
- Where
- 2 sites in Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
All of the Icu Patients Over 18 Years Old Except Pregnant, Trauma and AKI Patients
The Impact of POCUS on Treatment Planning and Prognosis in the ICU
This study aims to understand how using bedside ultrasound in the intensive care unit (ICU) can improve diagnosis and treatment for critically ill patients.
- Trial name
- NCT06613464
- Testing
- diagnosis confirmation
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Döndü Genc Moralar
Influenza
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults
The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator.
- Trial name
- NCT00380211
- Testing
- Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
- Where
- 6 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Over 18 Years Old
Discharge Checklist for Stoma Management Skills
The aim of this study was to develop an Ostomy Management Skills Discharge Checklist and to prospectively compare individuals who received this list with those who received standard discharge training to monitor its impact on…
- Trial name
- NCT07289841
- Testing
- Stoma Management Skills Discharge Checklist used
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Neslihan Özcanarslan
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Amputation Stumps, Pain
2PX (Topical Strontium Chloride Hexahydrate) in Patients With Post-Amputation Stump Pain.
The objective of this study is to investigate the analgesic effect of topical strontium chloride in stump pain, and to prospectively determine other efficacy and safety measures of topical strontium chloride in stump pain.
- Trial name
- NCT00592098
- Testing
- Strontium chloride hexahydrate
- Where
- Norway
- Volunteers
- 22 people
- Sponsor
- SantoSolve AS
Contraception
Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women
Purpose of the study is to investigate safety and contraceptive efficacy of an LNG-containing intravaginal ring.
- Trial name
- NCT02403401
- Testing
- Levonorgestrel (BAY98-7196)
- Where
- 100 sites in United States, Japan
- Volunteers
- 1,471 people
- Sponsor
- Bayer
Chronic Hand Dermatitis
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis
Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate…
- Trial name
- NCT00226707
- Testing
- Pimecrolimus Cream 1%
- Volunteers
- 652 people
- Sponsor
- Novartis
Influenza Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
This study will evaluate the immunogenicity and safety of GSK Biologicals' Trivalent split virion influenza vaccine Fluviral for the 2008-2009 season in adults over the age of 18.
- Trial name
- NCT00718120
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old
This is an open study of the use of AdimFlu-S (2010-2011 season) vaccine in young subjects aged between 6 months old to 18 years old. All participants will be divided into three age cohorts.
- Trial name
- NCT01356342
- Testing
- AdimFlu-S 2010-2011, inactivated
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Stroke, Sensorimotor Impairment Affecting the Upper Limb
Reliability of Sensor-Derived Measurements of the SENSorized Fugl-Meyer (FMA) in Subjects with Stroke Outcomes
This study will be conducted at a single research center, the main objective of the study will be to evaluate the efficacy, safety, and accuracy of a medical device that has not yet been commercialized; therefore, it is still…
- Conditions
- Stroke, Sensorimotor Impairment Affecting the Upper Limb, 18 Years and Over
- Trial name
- FMA-SENS (NCT06893367)
- Testing
- IMU and RealSense Cameras
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Yellow Fever
Phase 3 Single Arm, Open Study on vYF in Adults
The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan. Study details include: The study duration will be up to approximately 1 month.
- Trial name
- NCT07222059
- Testing
- Yellow fever vaccine (live)
- Where
- 4 sites in Japan
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Homozygous Familial Hypercholesterolemia (HoFH)
A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia
The purpose of the study is to evaluate the safety of Rosuvastatin in Children and Adolescents with Homozygous Familial Hypercholesterolemia.
- Trial name
- NCT02434497
- Testing
- Rosuvastatin 20mg
- Where
- 6 sites in Belgium, Canada and 4 more
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Women and Men Over 18 Years Old, AF Ablation (ECS recommendation2020&ACS2014) Either for Paroxysmal AF Unresponsive to Anti-arrhythmic Treatment Either for Persisting Symptomatic AF
Predictive Properties of Myocardial Fibrosis Biomarkers on the Outcome of Atrial Fibrillation Ablation
Atrial fibrillation (AF) is the most common cardiac arrhythmia. As an independent predictor of cardiovascular mortality, particularly for stroke, its management is a real public health issue.
- Conditions
- Women and Men Over 18 Years Old, AF Ablation (ECS recommendation2020&ACS2014) Either for Paroxysmal AF Unresponsive to Anti-arrhythmic Treatment Either for Persisting Symptomatic AF, Able to Give His Non Opposition to Participate to the Study
- Trial name
- PROFIB-AF (NCT05179902)
- Where
- France
- Volunteers
- 190 people
- Sponsor
- University Hospital, Clermont-Ferrand
SARS-CoV2, Covid19
A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults
This study is being conducted to look at the safety and immune response (how the immune system of the human body reacts) to a vaccine for SARS-CoV-2 (the virus responsible for COVID-19 infection) when administered as an…
- Trial name
- NCT04495933
- Testing
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
- Where
- Australia
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- The University of Queensland